Related Experiment Video
Updated: Aug 17, 2026

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence
Published on: October 25, 2011
A phase II trial of CI-958 in recurrent platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study
M A Hoffman1, J A Blessing, E R Nuñez
1Division of Hematology-Oncology, Long Island Jewish Medical Center, Campus of the Albert Einstein College of Medicine, New Hyde Park, New York 11040, USA. hoffman@lij.edu
Objectives:
To estimate the antitumor efficacy of CI-958 in patients with measurable recurrences of platinum-sensitive ovarian carcinoma and to determine the nature and degree of toxicity of CI-958 in these patients.
Methods:
Patients received CI-958 560 mg/m2 intravenously every 3 weeks and tumor measurements were performed every one to two cycles.
Results:
Of 23 patients entered in the study, there was one complete response and 10 patients had stable disease with short response durations.
Conclusions:
CI-958 has minimal activity in recurrent platinum-sensitive ovarian carcinoma at the dose and schedule tested.
Related Concept Videos
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Treatment Resistent Cancers
Clinical Trials
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview

